Molecular Epidemiology and Genetic Evolution Analysis of Porcine Reproductive and Respiratory Syndrome Virus in Southern Xinjiang, China, from 2023 to 2025

2023年至2025年中国新疆南部猪繁殖与呼吸综合征病毒的分子流行病学和遗传进化分析

阅读:1

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV), a major pathogen causing substantial economic losses in the global swine industry, was studied in southern Xinjiang to characterize its local epidemic features. Based on 632 clinical samples collected from 13 pig farms between 2023 and 2025, quantitative RT-PCR detection showed an overall positivity rate of 18.35% (116/632), with PRRSV-2 single infection accounting for 97.41% (113/116), PRRSV-1 single infection for 1.72% (2/116), and co-infection for 0.86% (1/116). Among 38 ORF5 sequences obtained from positive samples, Sublineage 1.8 (NADC30-like) was dominant, comprising 97.14% of successfully sequenced strains. Molecular analysis revealed that PRRSV-1 isolates carried six amino acid mutations including A129V (consistent with the Chinese strain CN/FJFQ-1/2023), while PRRSV-2 strains exhibited key variations such as the neutralization escape mutation Q13R, virulence-associated site K151R, and an anomalous vaccine marker A137. Furthermore, a recombinant strain (XJLETUQ2025-7) between NADC30 and VR-2332 was identified with breakpoints in NSP2 and NSP10. Serological surveillance of 2043 vaccinated pigs showed an overall antibody positive rate of 83.0% (1696/2043), with increasing annual rates from 72.3% (2023) and 75.4% (2024) to 91.3% (2025). In conclusion, the PRRSV epidemic in southern Xinjiang is primarily driven by NADC30-like strains of PRRSV-2, with recombination events and GP5 epitope variations posing challenges to disease control. These findings enhance the epidemiological understanding of PRRSV in the region and provide valuable insights for vaccine development and prevention strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。